Market revenue in 2023 | USD 115.1 million |
Market revenue in 2030 | USD 177.3 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Modified/attenuated live |
Fastest growing segment | Inactivated (Killed) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Modified/Attenuated Live, Inactivated (Killed) |
Key market players worldwide | Boehringer Ingelheim, Merck & Co Inc, Virbac SA, Elanco Animal Health Inc, Zoetis Inc Class A, Bioveta, Hester Biosciences, Brilliant Bio Pharma, HESKA, Zendal |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dog vaccines market will help companies and investors design strategic landscapes.
Modified/attenuated live was the largest segment with a revenue share of 52.22% in 2023. Horizon Databook has segmented the Canada dog vaccines market based on modified/attenuated live, inactivated (killed) covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada dog vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Canada dog vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account